IP Library Granted Patent US 11,731,983
Granted Patent B2
US 11,731,983 · App. 17/349,584 · Granted Aug 22, 2023

Production method of thienopyrimidine derivative

Inventor: Kazuhiro Miwa (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D495/04C07D333/38C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,731,983
App. No.
17/349,584
Granted
Aug 22, 2023
Kind
B2
Abstract

The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.

Claims (10)

1. A method of producing 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine -2,4(1H,3H)-dione, or a salt thereof, which comprises subjecting 1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine -2,4(1H,3H)-dione, or a salt thereof, to a reduction reaction.

2. The method of claim 1 , wherein the reduction reaction is performed in the presence of a catalyst.

3. The method of claim 2 , wherein the catalyst is used in an amount of the range of 0.01 g to 0.2 g per 1 g of the 1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine -2,4(1H,3H)-dione, or salt thereof.

4. The method of claim 2 , wherein the catalyst is palladium on carbon, palladium hydroxide on carbon, or platinum on carbon.

5. The method of claim 4 , wherein the catalyst is used in an amount of the range of 0.01 g to 0.2 g, per 1 g of the 1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-6-(4-nitrophenyl)thieno[2,3-d]pyrimidine -2,4(1H,3H)-dione, or salt thereof.

6. The method of claim 1 , wherein the reduction reaction is performed in the presence of an acid.

7. The method of claim 6 , wherein the acid is hydrochloric acid, a hydrogen chloride/methanol solution, formic acid, or acetic acid.

8. The method of claim 1 , wherein the reduction reaction is performed under a hydrogen pressure in the range of the range of 0.05 MPa to 0.4 MPa.

9. The method of claim 1 , wherein the reduction reaction is performed at a temperature between 10° C. to 40° C.

10. The method of claim 1 , wherein the reduction reaction is performed in a solvent comprising methanol, ethanol, or tetrahydrofuran.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: FUKUOKA, KOICHIRO; MIWA, KAZUHIRO; SASAKI, TSUYOSHI; KOMURA, FUMIYA
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056568/0520 →
Priority Claims (1)
JP 2012/217679 · Sep 28, 2012 · national
Continuity (5)
Continuation 16710390 · Dec 11, 2019
Continuation 16116804 · Aug 29, 2018
Division 15481505 · Apr 7, 2017
Division 14432188
Related Publication 20220135585A1 · May 5, 2022
Cited By (6)
US 12,325,714 US 12,336,990 US 12,338,249 US 12,551,447 US 12,629,370 US 12,655,154